Remove Heart Attack Remove Heart attacks Remove Innovation
article thumbnail

MMRI Publishes Breakthrough Study Detailing a Novel Approach to Minimize Damage After a Heart Attack

DAIC

associate professor of biomedical research and translational medicine and scientific operations director at MMRI , recently published an innovative manuscript titled, Biomimetic Nanomaterials for the Immunomodulation of the Cardiosplenic Axis Post-Myocardial Infarction. McCarthy, Ph.D. McCarthy, Ph.D., Rajendran JC Bose, Ph.D.,

article thumbnail

National Cardiogenic Shock Initiative Study Results Show Significant Increase in Heart Attack Survival

DAIC

The typical survival rate of this deadly complication during a heart attack has historically hovered around 50%. Final results from the national study published in the Journal of the American Heart Association were achieved from looking at 406 patients from hospitals across 29 states. In the U.S.,

article thumbnail

RCE Technologies, Inc. Announces First-In-Human Transdermal Continuous Cardiac Biomarker Monitoring

DAIC

RCE) is an innovative artificial intelligence (AI) based medical technology company dedicated to early heart attack detection. RCE) is an innovative artificial intelligence (AI) based medical technology company dedicated to early heart attack detection. RCE Technologies, Inc. Featured in an ACC.24

article thumbnail

AliveCor Announces Dual FDA Clearance of AI Technology That Delivers 35 Cardiac Determinations and First-of-its-Kind Kardia 12L ECG System

DAIC

This is the world’s first AI that can detect life-threatening cardiac conditions, including heart attacks, using a reduced leadset. KAI 12L can seamlessly integrate with compatible devices, including the Kardia 12L ECG System, expanding critical access to accurate heart data within a broad range of healthcare settings.

article thumbnail

DAIC's Top 10 for April

DAIC

Clinical trials and innovative technology took center stage during the month of April, racking up some record number views. 24: SGLT-2 Inhibitors Show Mixed Results After Heart Attack 10. Here is a look at what DAIC viewers were reading last month: 1. EMPACT-MI Trial Outcomes Reported at ACC.24:

article thumbnail

Cleerly Receives FDA Breakthrough Device Designation for Heart Disease Risk Staging System

DAIC

Its purpose is to support physicians with a more accurate and personalized risk assessment for patients at risk of major adverse cardiovascular events (MACE), including heart attacks, before they happen. Min , MD, Founder and CEO of Cleerly.

article thumbnail

Cleerly Raises $106 Million in Series C Extension Funding

DAIC

We are very excited to see our purpose-driven mission come to life, making advanced cardiac care accessible to more patients and working towards our goal of eliminating heart attacks.” “We We are excited to support Cleerly in its mission to revolutionize cardiac care,” said Scott Barclay, Managing Director at Insight Partners.